Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna confirms discussions with MHLW to supply Japan with 40 million doses of mRNA vaccine against COVID-19 (mRNA-1273)

Moderna Confirms Discussions with the Ministry of Health, Labour and Welfare to Supply Japan with 40 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

How Moderna Will Fare After Posting Strong Clinical Results

Two Moderna Inc (NASDAQ: MRNA) analysts issued snapshots this week on the progress of the company's coronavirus vaccine program.

2 Moderna Analysts On Chances Of COVID-19 Vaccine Approval, Upcoming Catalysts

Moderna (MRNA) is making significant progress in development of coronavirus vaccine. The vaccine is currently in phase III study.

Moderna Stock Surges 260% YTD on Coronavirus Vaccine Progress

Results from a small clinical trial involving elderly patients cheered investors.

Why Moderna Stock Zoomed Higher on Wednesday

Netflix

Fresh records for the Nasdaq and S&P 500 have become almost commonplace.

Markets Rocket Higher as Moderna Coronavirus Vaccine Shows Promise, Netflix Stays Sticky

Moderna Inc (NASDAQ: MRNA) shares were moving to the upside Wednesday following the company's presentation of new interim safety and immunogenicity data from cohorts of older adults in the Phase 1 study of its coronavirus vaccine candidate codenamed mRNA-1273.

New Moderna Data: Coronavirus Vaccine Candidate Equally Effective In Older Adults

The levels of antibodies produced by mRNA-1273 were comparable to those seen in younger adults, the company said.

Moderna Reports Positive Results for Coronavirus Vaccine Candidate in Elderly Patients

The biotech company’s small preliminary study indicates the vaccine produced similar levels of antibodies for younger people and those aged 56 and older.

Moderna Says Its Covid-19 Vaccine Shows Promising Results For Older Adults

If a company can come up with a cure or a vaccine for COVID-19, there may be limitless gains.

Analyst Sees Moderna as Cheap Ahead of Interim COVID-19 Data

Shares of Moderna Inc. MRNA, +4.93% gained 5.2% in trading on Wednesday after a company executive told a government advisory committee that its experimental COVID-19 vaccine had triggered antibodies in elderly patients.

Moderna's stock rises after it says COVID-19 vaccine candidate produced antibodies in older patients

Moderna says its coronavirus vaccine trial proved safe, well-tolerated and effective in a Phase 1 test for participants ages 18 to more than 71, as a crucial Phase 3 vaccine trial continues.
The post Moderna Posts Positive Data On Early Coronavirus Vaccine Trial appeared first on Investor's Business Daily.

Moderna Posts Positive Data On Early Coronavirus Vaccine Trial

The vaccine was tested on 10 adults between the ages of 56 and 70 and 10 elderly adults aged 71 and older, Moderna said.

Moderna says its coronavirus vaccine shows promising results in small trial of elderly patients

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna to present new interim clinical data on mRNA-1273 at Advisory Committee on Immunization Practices (ACIP) Meeting.

Moderna to Present New Interim Clinical Data About mRNA Vaccine Against COVID-19 (mRNA-1273) at Advisory Committee on Immunization Practices (ACIP) Meeting

Livongo Health Inc

Regeneron Pharmaceuticals

The highly defensive healthcare sector was a popular place for successful money managers to put their money to work in the second quarter.

3 Healthcare Stocks Billionaires Wouldn't Stop Buying in Q2

Inovio Pharmaceuticals

Novavax

Sanofi

Sorrento Therapeutics Inc

These are the top stocks to buy based on the 2020 U.S. presidential election, with new stock picks updated daily from the sharpest investing minds in the business.

Investing for the Election: 6 Vaccine Stocks to Buy for Operation Warp Speed

Even a vaccine that's 50% effective with some side effects would be a game changer. The Trump Administration is throwing billions into that hope and investors are seeing big profits.

6 Hot Coronavirus Stocks Moving At “Warp Speed”

Moderna Inc (NASDAQ: MRNA), one of the frontrunners in the coronavirus vaccine race, announced Monday it's closing in on signing a new supply agreement.

Moderna In Talks To Supply 80M Doses Of Coronavirus Vaccine To European Commission

Moderna on Monday announced it's near a supply deal in Europe and that its coronavirus vaccine testing enrollment of 30,000 participants by September is on pace, but MRNA stock slipped.
The post Moderna Near Deal To Supply Coronavirus Vaccine To Europe appeared first on Investor's Business Daily.

Moderna Near Deal To Supply Coronavirus Vaccine To Europe

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna confirms advanced discussions with European Commission to supply Europe with 80 million doses of mRNA vaccine against COVID-19 (mRNA-1273).

Moderna Confirms Advanced Discussions with European Commission to Supply Europe with 80 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

The pandemic shows no signs of slowing, it's time to use any signs of weakness in coronavirus stocks as a buying opportunity.
The post 3 Coronavirus Stocks to Go on the Defensive appeared first on InvestorPlace.

3 Coronavirus Stocks to Go on the Defensive

CureVac B.V

Two promising biotechs with COVID-19 vaccine candidates in development. One of them is the more likely winner.

Better Coronavirus Stock: CureVac vs. Moderna

AstraZeneca

Pfizer

Coronavirus vaccine companies are attacking the virus and have late-stage trials underway. But the Covid vaccine timeline may not be what you think.

Coronavirus Vaccine Companies Target Best-Case Timeline — But What's The Worst Case?

Those who bought MRNA stock may be cashing out. But with risk/return still in your favor, taking a small position may be worthwhile.

After Vaccine Deal, Buy The Dip With Moderna Stock

BioNTech SE

Johnson & Johnson

Merck

What’s the best way for investors to gain diversified exposure to today's leading vaccine research? Here he recommends a 5-stock portfolio to boost your chances to benefit from potential progress made toward a successful Covid vaccine.

News for Moderna Stock (MRNA)